Secondary polycythemia develops when the oxygen-sensing EPO pathway signals the marrow to increase red blood cell mass to enhance tissue oxygen delivery. The trigger is outside the marrow, so treatment focuses on that driver rather than a fixed hematocrit target. [2]

• Systemic hypoxia leads to kidney EPO upregulation: Chronic low oxygen levels stabilize HIF-2α in renal peritubular cells, increasing erythropoietin and red cell production. Typical contexts include sleep-disordered breathing, chronic lung disease, or heart disease. [3]
• Local renal hypoxia or ischemia: Conditions that reduce renal blood flow can drive focal EPO excess, even when arterial oxygen levels appear acceptable.[2][4]
• Ectopic EPO from tumors: Some neoplasms produce erythropoietin outright; classic examples include renal cell carcinoma, hepatocellular carcinoma, and hemangioblastoma. In the case of EPO-secreting tumors, tumor removal is curative, with erythrocytosis resolving following tumor treatment. [2]
• Carbon monoxide exposure: CO from tobacco or environmental sources forms carboxyhemoglobin, which lowers effective oxygen delivery and stimulates EPO despite a normal pulse oximetry reading. [5]
• High-affinity hemoglobin or low 2,3-BPG states: In these conditions, the lungs deliver oxygen to the blood normally, and the arterial oxygen level (arterial oxygen pressure) is normal. The problem is that hemoglobin holds onto oxygen too tightly, so the tissues do not receive enough of it. A low ‘P50’ value on an oxygen–hemoglobin dissociation test is the key clue. [3]
• Medications and hormones: Testosterone and exogenous EPO increase erythropoiesis by stimulating EPO production and improving iron availability; counts typically fall when exposure is reduced or stopped. [6]

Key idea: In secondary polycythemia, the marrow is responding to external signals; identifying and correcting those signals is the cornerstone of care.

Symptoms arise from the thicker blood and the underlying condition that drives the high red cell count.

Common viscosity symptoms

Headache, dizziness, blurred vision, fatigue, facial redness, and tingling fingertips. These reflect increased blood viscosity due to an elevated red blood cell count. [2][7]

When to seek urgent care

If you experience any signs of thrombotic complications, please seek medical attention immediately. Chest pain, shortness of breath at rest, one-sided weakness, trouble speaking, or vision loss requires emergency evaluation to rule out clotting or other serious complications. [2][8]

Doctors follow a simple sequence: first, they verify that the red cell rise is real and persistent; then, they rule out polycythemia vera (PV); and finally, they investigate the cause.

1. Confirm that the increase is real

Your clinician repeats the complete blood count after ensuring adequate hydration and reviews previous results to exclude low plasma volume, recent illness, or diuretic use. A smear and iron studies help interpret numbers, since iron deficiency can hide or mimic changes. [2][8]

2. Check oxygen and exposures

Tests may include pulse oximetry, an arterial blood gas, a carboxyhemoglobin level if you smoke, and a sleep study if obstructive sleep apnea is suspected [8]. Further testing is needed if symptoms point that way.

1. Use two key blood tests to separate secondary causes from PV

• Erythropoietin (EPO): Often normal or high in secondary polycythemia. Results are interpreted in conjunction with symptoms and medical history. [8]
• JAK2 mutation test: Start with JAK2 V617F. If negative and PV still fits, test exon 12. A positive JAK2 with compatible labs points to PV rather than a secondary process. [8]

1. Order targeted tests for specific causes when clues are present

• High-affinity hemoglobin or low 2,3-BPG: An oxygen–hemoglobin dissociation P50 test explains lifelong or family-pattern erythrocytosis with normal oxygen levels. [8]
• EPO-producing tumors: Kidney, liver, brain, or spine imaging if symptoms suggest a mass. Red cell counts often decline after tumor treatment. [9][10]
• Medication review: Androgens such as testosterone and injected EPO can raise counts; dosing may need adjustment.[2]

1. Bone marrow is not routine

• If PV remains a concern after JAK2 and EPO testing, a bone marrow examination can help finalize the diagnosis. It is not required in most secondary cases. [8]

Treatment focuses on the cause, not a one-size-fits-all hematocrit target. Your care team will tailor the plan to your specific symptoms, oxygen status, and cardiovascular risk.

Start by fixing the driver:

• Sleep apnea: Using a consistent CPAP can lower hemoglobin and hematocrit levels. [11]
• Chronic lung or heart disease: Oxygen therapy and disease-specific care help reduce the low-oxygen signal that triggers red blood cell production. [12]
• Smoking or carbon monoxide: Stopping exposure reverses carboxyhemoglobin-related erythrocytosis. [13]
• Medicines and hormones: Review testosterone, exogenous EPO, and other contributing factors; adjust as appropriate. [2]
• EPO-secreting tumors: Treat the cancer; red cell counts often fall after control or removal of the tumor. [10]

When phlebotomy is considered

Phlebotomy can help relieve symptoms or prepare for surgery. It is not applied on autopilot and targets comfort and safety, not a fixed PV-style number. Use cautiously in individuals who rely on higher red blood cells for oxygen delivery, and avoid iron deficiency from excessive phlebotomy. [2]

Aspirin is not automatic

Low-dose aspirin may be used based on overall cardiovascular risk, rather than simply because the hematocrit is high. Decisions are individualized. [2][14][8]

Follow-up and safety checks

Plan periodic CBCs, review symptoms, and reassess oxygen status after treatment changes. Revisit the diagnosis if the pattern shifts or if PV becomes a concern again.

No, secondary polycythemia refers to a high red blood cell count caused by another underlying condition. Many causes are not cancer, such as sleep apnea, chronic lung or heart disease, smoking or carbon-monoxide exposure, high altitude, or medicines like testosterone. Treating the cause usually brings counts down. [2]

Some causes are cancers that make extra erythropoietin (EPO). Classic examples include renal cell carcinoma, hepatocellular carcinoma, and hemangioblastoma. When these tumors are treated, red cell counts often fall. [10][2][9]

By contrast, polycythemia vera (PV) is a blood cancer, typically associated with a JAK2 mutation. It is managed with PV-specific goals, such as maintaining hematocrit levels within a safe range and reducing the risk of blood clots. [8]

Most people do relatively well once the underlying cause is found and treated [2]. Prognosis depends far more on the cause than on the high red cell count itself.

What improves outlook

• Treating low-oxygen states: Using CPAP to treat sleep apnea often lowers hemoglobin and hematocrit levels/hematocrit and symptoms; outcomes correlate with the degree of sleep apnea control. [11][6]
• Stopping exposures: Quitting smoking or avoiding carbon monoxide removes the signal to overproduce red cells. [15]
• Treating EPO-secreting tumors: Counts frequently fall after tumor control or removal; the long-term outlook then depends on the tumor’s stage and biology. [10]

What really drives risk

• The primary condition (for example, COPD, heart disease, or cancer) determines long-term health more than the erythrocytosis label. Managing that condition, along with standard cardiovascular risk factors, matters most. [16]
• Routine phlebotomy is not automatically beneficial and can cause iron deficiency when red blood cells are compensating for low oxygen levels (e.g., cyanotic heart disease). Use phlebotomy selectively for symptoms or perioperative needs. [2]

The cause usually drives life expectancy in secondary polycythemia. Identify it early, treat it well, and monitor blood counts and symptoms over time. [2][8]

1. What is the most common cause of secondary polycythemia?

Low oxygen is the usual driver. Typical examples are obstructive sleep apnea and chronic lung or heart disease. Smoking and carbon-monoxide exposure are also frequent triggers. [2]

2. Can secondary polycythemia turn into polycythemia vera (PV)?

No. Secondary polycythemia is a response to the underlying condition. PV is a clonal blood cancer, usually linked to a JAK2 mutation, and is a different diagnosis. [8]

3. What tests confirm the cause?

Most workups include an erythropoietin (EPO) level, JAK2 testing to rule out PV, and oxygen checks. Depending on clues, doctors may add a P50 test for high-affinity hemoglobin and imaging to look for EPO-secreting tumors. [2][8][10]

4. Do I always need phlebotomy?

No. Phlebotomy is used selectively for symptom relief or as a pre-procedure measure. In conditions that depend on higher red cells for oxygen delivery, routine phlebotomy can do more harm than good. [14][8]

5. Will CPAP help if my cause is sleep apnea?

Yes, consistent CPAP often lowers hemoglobin and hematocrit and improves symptoms when sleep apnea is the driver. [11]

• 2,3-BPG – 2,3-bisphosphoglycerate (a molecule in red blood cells that helps hemoglobin release oxygen to tissues)
• ABG – Arterial blood gas (a blood test that directly measures oxygen and carbon dioxide levels)
• CBC – Complete blood count (standard blood test that reports red cells, white cells, and platelets)
• COPD – Chronic obstructive pulmonary disease (long-term lung disease such as chronic bronchitis or emphysema)
• CPAP – Continuous positive airway pressure (a machine that keeps the airway open during sleep in obstructive sleep apnea)
• EPO – Erythropoietin (a hormone, mainly made by the kidneys, that tells the bone marrow to make more red blood cells)
• Hct – Hematocrit (the percentage of blood made up of red blood cells)
• HIF-2α – Hypoxia-inducible factor-2 alpha (a protein that turns on genes, including EPO, when oxygen is low)
• ICD-10 – International Classification of Diseases, 10th Revision (coding system used to classify diagnoses)
• JAK2 – Janus kinase 2 (a signaling protein; certain JAK2 mutations are typical of polycythemia vera)
• PaO₂ – Arterial partial pressure of oxygen (a measure of oxygen level in arterial blood)
• P50 – Oxygen–hemoglobin dissociation P50 (the oxygen pressure at which hemoglobin is 50% saturated; used to detect high-affinity hemoglobin)
• PV – Polycythemia vera (a type of blood cancer in which the bone marrow makes too many red blood cells)
• RBC – Red blood cell
• SaO₂ / SpO₂ – Arterial oxygen saturation (percentage of hemoglobin carrying oxygen, usually measured by pulse oximeter)

1. Mithoowani, S., Laureano, M., Crowther, M. A., & Hillis, C. M. (2020). Investigation and management of erythrocytosis. Cmaj, 192(32), E913-E918.
2. Haider MZ, Anwer F. Secondary Polycythemia. [Updated 2023 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562233/
3. Gangat, N., Szuber, N., & Tefferi, A. (2023). JAK2 unmutated erythrocytosis: 2023 update on diagnosis and management. American journal of hematology, 98(6), 965-981.
4. Katiyar, V., Aijaz, T., Lingamaneni, P., Vohra, I., & Cisak, K. (2021). Polycythemia in a Patient With Atonic Bladder and Hydronephrosis. Cureus, 13(9), e18094. https://doi.org/10.7759/cureus.18094
5. Van Staden, S. R., Groenewald, M., Engelbrecht, R., Becker, P. J., & Hazelhurst, L. T. (2013). Carboxyhaemoglobin levels, health and lifestyle perceptions in smokers converting from tobacco cigarettes to electronic cigarettes. South African medical journal, 103(11), 865-868.
6. Bachman, E., Travison, T. G., Basaria, S., Davda, M. N., Guo, W., Li, M., ... & Bhasin, S. (2014). Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences, 69(6), 725-735.
7. Keohane, C., McMullin, M. F., & Harrison, C. (2013). The diagnosis and management of erythrocytosis. Bmj, 347.
8. McMullin, M., Harrison, C., Ali, S., Cargo, C., Chen, F., Ewing, J., ... & Mead, A. (2018). A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. British journal of haematology, 184(2).
9. Lee, Y., Cheng, S. M., Hwang, D. Y., Chiu, Y. L., & Chou, Y. H. (2024). Polycythemia secondary to renal hemangioblastoma: a case report and literature review. International Journal of Surgical Pathology, 32(1), 140-144.
10. Rose, T. L., & Kim, W. Y. (2024). Renal Cell Carcinoma: A Review. JAMA, 332(12), 1001–1010. https://doi.org/10.1001/jama.2024.12848
11. Zeng, Z., Song, Y., He, X., Yang, H., Yue, F., Xiong, M., & Hu, K. (2022). Obstructive Sleep Apnea is Associated with an Increased Prevalence of Polycythemia in Patients with Chronic Obstructive Pulmonary Disease. International journal of chronic obstructive pulmonary disease, 17, 195–204. https://doi.org/10.2147/COPD.S338824
12. Chambellan, A., Chailleux, E., & Similowski, T. (2005). Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest, 128(3), 1201-1208.
13. Castleden, C. M., & Cole, P. V. (1975). Carboxyhaemoglobin levels of smokers and non-smokers working in the City of London. Occupational and Environmental Medicine, 32(2), 115-118.
14. McMullin, M. F. F., Mead, A. J., Ali, S., Cargo, C., Chen, F., Ewing, J., Garg, M., Godfrey, A., Knapper, S., McLornan, D. P., Nangalia, J., Sekhar, M., Wadelin, F., Harrison, C. N., & British Society for Haematology Guideline (2019). A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. British journal of haematology, 184(2), 161–175. https://doi.org/10.1111/bjh.15647
15. Buczkowski, K., Dachtera-Frąckiewicz, M., Luszkiewicz, D., Klucz, K., Sawicka-Powierza, J., & Marcinowicz, L. (2021). Reasons for and Scenarios Associated with Failure to Cease Smoking: Results from a Qualitative Study Among Polish Smokers Who Had Unsuccessfully Attempted to Quit. Patient preference and adherence, 15, 2071–2084. https://doi.org/10.2147/PPA.S320798
16. Galeas, J. N., Yu, Y., Polineni, R., Sukrithan, V., Tegla, C., Verma, A., & Goel, S. (2015). Polycythemia Vera vs. Secondary Erythrocytosis Mortality Outcome in a Multiracial Inner City Cohort. Blood, 126(23), 5183.